查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年奈米醫學市場預測：按產品類型、模式、適應症、應用和地區進行的全球分析
市場調查報告書
商品編碼
1383467

2030 年奈米醫學市場預測：按產品類型、模式、適應症、應用和地區進行的全球分析

Nanomedicine Market Forecasts to 2030 - Global Analysis By Product Type (Nanoparticles, Nano Tubes, Nano Devices, Nano Shells and Other Product Types), Modality (Treatment and Diagnostics), Indication, Application and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球奈米藥物市場規模為4.3284億美元，預計到2030年將達到11.3051億美元，預測期內年複合成長率為14.7%。

奈米技術在醫療保健中的創新應用被稱為奈米醫學。它利用了 10-9 m 奈米尺度材料的特性，從生物、化學和物理角度來看，這些特性通常與較大尺寸的相同材料不同。此外，由於人體內的許多生物過程都是在奈米尺度上進行的，因此奈米材料和奈米顆粒可以克服其預期輸送系統的障礙，並可用於血液以及器官、細胞和組織內。不同程度地含有小蛋白質和DNA。

根據美國美國的死亡病例是死於心臟病。

慢性病增加

隨著糖尿病、癌症、心血管疾病和神經退化性疾病等慢性病的全球負擔日益加重，迫切需要先進的醫療解決方案。此外，奈米醫學在提供針對性干涉、早期疾病檢測和更有效治療方面的潛力滿足了越來越多患有這些慢性疾病的患者的需求。

開發價高

由於這些技術非常複雜，開發奈米醫學領域的新產品需要大量資金。此外，設計和測試奈米級藥物傳輸系統、診斷設備和奈米顆粒都是研發過程的一部分，這可能是資源密集的。對於新興企業和小型企業來說，高昂的開發成本可能會成為進入障礙。

藥物給藥的進展

奈米醫學驅動的藥物傳輸系統的不斷進步為最佳化藥物給藥提供了前景。透過減少給藥次數並提供受控和持續的藥物釋放，這些創新有可能提高患者的醫囑遵從性和依從性。此外，這不僅提高了患者滿意度，還提高了治療效果，特別是在治療慢性疾病時。

社會和道德問題

社會對醫學奈米技術的接受和認知可能會受到有關資料安全、隱私和奈米設備潛在濫用的道德擔憂的影響。此外，為了獲得公眾信任並克服對奈米醫學的抵制，需要解決這些道德問題並負責任地進行開發。

COVID-19 的影響：

奈米醫學市場受到了 COVID-19大流行的各種影響。這場大流行凸顯了對尖端醫療程序、治療方法和免疫接種的需求，但它也擾亂了供應鏈，推遲了研究舉措，並將資金轉移到了大流行應對工作上。從積極的一面來看，新的藥物傳輸方法、奈米級 COVID-19 疫苗和診斷都可以透過奈米醫學實現。然而，由於大流行的經濟影響，一些奈米醫學舉措，特別是在學術和研究領域，面臨資金挑戰。

預計心血管疾病領域在預測期內將是最大的。

預計心血管疾病將佔據市場的最大佔有率。心臟和血管疾病，包括冠狀動脈疾病、高血壓、鬱血性心臟衰竭和心律不整，都被認為是心血管疾病。全世界心血管疾病的高盛行率及其對公共衛生的重大影響是該領域受到關注的原因。此外，藥品、醫療設備、診斷工具和介入手術都是心血管疾病市場的一部分。新治療方法的開拓、心血管手術和介入性心臟病學的進步都是推動這一市場擴張的主要因素。

預測期內，再生醫學領域預估複合年複合成長率最高

年複合成長率最高的市場是再生醫學領域。替代、再生和修復患病或受損組織和器官的治療方法方法和方法的開發被稱為再生醫學。這包括使用生物材料、組織工程和幹細胞療法來支持自然癒合過程。此外，人口高齡化、慢性病的增加以及可治療從神經系統疾病到心血管疾病等多種疾病的新療法的需求，是高年複合成長率的主要驅動力。

比例最高的地區：

由於完善的醫療基礎設施、高昂的醫療成本、活躍的高齡化多種因素，預計北美將佔據全球醫療保健市場的最大佔有率。此外，該地區尖端的醫療技術、製藥公司、一流的研究機構以及對創新的關注使其成為醫療保健領域的主要參與者。美國和加拿大在醫療進步和醫療保健服務方面處於領先地位，北美對新出現的醫療保健挑戰和醫療保健疾病的積極應對進一步鞏固了其在全球醫療保健市場的領導者地位。我正在這樣做。

複合年複合成長率最高的地區：

在全球醫療保健市場中，亞太地區的年複合成長率最高。推動這一巨大成長的因素有很多，包括該地區人口的不斷成長、醫療保健意識的提高、經濟的加速發展以及醫療保健服務的普及。此外，亞太地區吸引了製藥公司和醫療技術供應商的大量投資，使其成為臨床試驗和醫學研發的中心。因此，該地區在醫療保健基礎設施、新治療方法和數位醫療解決方案方面取得了快速進步，成為全球醫療保健產業成長和創新的關鍵催化劑。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球奈米醫學市場：依產品類型

  • 奈米顆粒
    • 金屬和金屬氧化物奈米顆粒
    • 脂質體
    • 聚合物和聚合物藥物綴合物
    • 水凝膠奈米顆粒
    • 樹枝狀聚合物
    • 無機奈米粒子
  • 奈米管
  • 奈米裝置
  • 奈米殼
  • 其他產品類型

第6章 全球奈米醫學市場：依形式分類

  • 過程
  • 診斷

第7章 全球奈米醫學市場：依適應症分類

  • 臨床腫瘤學
  • 感染疾病
  • 臨床循環系統
  • 泌尿系統
  • 眼科
  • 免疫學
  • 心血管疾病
  • 整形外科疾病
  • 神經系統疾病
  • 抗發炎疾病
  • 感染疾病對策
  • 其他適應症

第8章 全球奈米醫學市場：依應用分類

  • 藥物輸送
  • 診斷影像
  • 體外診斷
  • 植入
  • 再生醫學
  • 疫苗
  • 體外成像
  • 療法
  • 體內影像
  • 其他用途

第9章 全球奈米醫學市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • NanoCarrier Co. Ltd
  • Sanofi SA
  • Leadient BioSciences Inc.
  • Celgene Corporation
  • Abbott Laboratories
  • CombiMatrix Corporation
  • Johnson & Johnson Services Inc
  • Mallinckrodt Pharmaceuticals
  • Nanobiotix
  • Merck & Co., Inc.
  • Nanospectra Biosciences, Inc.
  • Gilead Sciences, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • GE Healthcare
  • Taiwan Liposome Company Ltd
  • Genzyme Corporation
Product Code: SMRC24315

According to Stratistics MRC, the Global Nanomedicine Market is accounted for $432.84 million in 2023 and is expected to reach $1130.51 million by 2030 growing at a CAGR of 14.7% during the forecast period. The innovative use of nanotechnology in healthcare is known as nanomedicine. It utilizes a material's properties at its nanometric scale of 10-9 m, which are frequently different from the same substance at a larger size in terms of biology, chemistry, and physics. Additionally, because many biological processes in the human body operate on a nanometric scale, nanomaterials and nanoparticles may be able to get past obstacles in the way of their intended delivery systems and interact at different degrees with small proteins or DNA in blood or within organs, cells, and tissues.

According to the Centres for Disease Control and Prevention, one in four fatalities in the United States occurred due to heart disease in 2021.

Market Dynamics:

Driver:

Growing chronic illness incidence

Advanced medical solutions are urgently needed as the burden of chronic diseases, such as diabetes, cancer, cardiovascular disease, and neurodegenerative disorders, is rising globally. Moreover, the potential of nanomedicine to provide targeted interventions, early disease detection, and more effective therapies is in line with the needs of an increasing number of patients suffering from these chronic illnesses.

Restraint:

High price of development

Due to the fact that these technologies are so complex, developing new products in the field of nanomedicine requires large financial outlays. Additionally, the design and testing of nanoscale drug delivery systems, diagnostic instruments, and nanoparticles are all part of the research and development process, which can be resource-intensive. For startups and smaller businesses, this high development cost may be a barrier to entry.

Opportunity:

Advances in drug administration

The ongoing advancement of drug delivery systems driven by nanomedicine presents prospects for optimizing the administration of medication. By lowering dosage frequency and offering controlled, sustained drug release, these innovations may enhance patient adherence and compliance. Furthermore, this improves patient satisfaction as well as the effectiveness of treatment, especially when managing chronic diseases.

Threat:

Social and ethical issues

Public acceptance and perception of nanotechnology in medicine may be impacted by ethical worries about data security, privacy, and possible misuse of nanoscale devices. Moreover, gaining the public's trust and overcoming resistance to nanomedicine require addressing these ethical issues and making sure that development is done responsibly.

COVID-19 Impact:

The market for nanomedicine has been impacted by the COVID-19 pandemic in a number of ways. The pandemic emphasized the need for cutting-edge medical procedures, therapies, and vaccinations, but it also caused supply chain disruptions, postponed research initiatives, and redirected funds toward pandemic response efforts. Positively, new drug delivery methods, COVID-19 vaccines at the nanoscale, and diagnostics were all made possible by nanomedicine. However, some nanomedicine initiatives faced funding difficulties as a result of the pandemic's economic effects, especially in the academic and research sectors.

The Cardiovascular Diseases segment is expected to be the largest during the forecast period

Cardiovascular diseases are predicted to hold the largest share in the market. Heart and blood vessel disorders, including coronary artery disease, hypertension, congestive heart failure, and arrhythmias, are all considered cardiovascular diseases. The high prevalence of cardiovascular diseases worldwide and their substantial impact on public health are the reasons for this segment's prominence. Moreover, pharmaceuticals, medical devices, diagnostic tools, and interventional procedures are all part of the cardiovascular disease market. The development of novel therapies, cardiac surgery advancements, and interventional cardiology has all been major factors in this market's expansion.

The Regenerative Medicine segment is expected to have the highest CAGR during the forecast period

The regenerative medicine segment holds the highest CAGR in the market. Developing treatments and methods to replace, regenerate, or repair diseased or damaged tissues and organs is known as regenerative medicine. It includes the use of biomaterials to support natural healing processes, tissue engineering, and stem cell therapies. Furthermore, the aging population, the rise in chronic illness, and the demand for novel treatments capable of curing a broad spectrum of illnesses, from neurological disorders to cardiovascular diseases, are the main causes of the high compound annual growth rate.

Region with largest share:

Due to a number of factors, including a well-established healthcare infrastructure, high healthcare expenditures, robust research and development activities, and an aging population with greater healthcare needs, North America is predicted to hold the largest share of the global healthcare market. Moreover, the region is a major player in the healthcare sector because of its cutting-edge medical technologies, pharmaceutical companies, top research institutions, and strong emphasis on innovation. With the United States and Canada at the forefront of medical advancements and healthcare services, North America's proactive response to emerging healthcare challenges and diseases further solidifies its position as a leader in the global healthcare market.

Region with highest CAGR:

In the global healthcare market, the Asia-Pacific region has the highest CAGR. Numerous factors, such as the region's expanding population, growing awareness of healthcare, accelerating economic development, and improved access to healthcare services, are driving this amazing growth. Additionally, the Asia-Pacific area has drawn large investments from pharmaceutical firms and suppliers of medical technology, making it a hub for clinical trials, medical research, and development. Consequently, the region is experiencing swift progress in healthcare infrastructure, novel therapies, and digital health solutions, thereby establishing itself as a primary catalyst for growth and innovation in the global healthcare industry.

Key players in the market

Some of the key players in Nanomedicine market include: NanoCarrier Co. Ltd, Sanofi SA, Leadient BioSciences Inc., Sigma-Tau Pharmaceuticals, Inc., Celgene Corporation, Abbott Laboratories, CombiMatrix Corporation, Johnson & Johnson Services Inc, Mallinckrodt Pharmaceuticals, Nanobiotix, Merck & Co., Inc., Nanospectra Biosciences, Inc., Gilead Sciences, Inc., Arrowhead Pharmaceuticals, Inc., Novavax, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GE Healthcare, Taiwan Liposome Company Ltd and Genzyme Corporation.

Key Developments:

In October 2023, Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, announced a development and commercialization agreement with Sanofi for Janssen's extraintestinal pathogenic Escherichia coli (ExPEC) investigational vaccine program. The lead vaccine candidate is currently being evaluated in the Phase 3 E.mbrace study for the prevention of invasive E. coli disease (IED) in adults aged 60 years and older.

In October 2023, Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, currently in Phase 3. The agreement brings together Janssen's robust science behind this potential first-in-class product and Sanofi's worldwide manufacturing footprint and recognized world-class expertise in launching innovative vaccines.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Product Types Covered:

  • Nanoparticles
  • Nano Tubes
  • Nano Devices
  • Nano Shells
  • Other Product Types

Modalities Covered:

  • Treatment
  • Diagnostics

Indications Covered:

  • Clinical Oncology
  • Infectious Diseases
  • Clinical Cardiology
  • Urology
  • Ophthalmology
  • Immunology
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Neurological Diseases
  • Anti-Inflammatory Diseases
  • Anti-Infective Diseases
  • Other Indications

Applications Covered:

  • Drug Delivery
  • Diagnostic Imaging
  • In vitro Diagnostics
  • Implants
  • Regenerative Medicine
  • Vaccines
  • In-Vitro Imaging
  • Therapeutics
  • In-vivo Imaging
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanomedicine Market, By Product Type

  • 5.1 Introduction
  • 5.2 Nanoparticles
    • 5.2.1 Metal & Metal Oxide Nanoparticles
    • 5.2.2 Liposomes
    • 5.2.3 Polymers & Polymer Drug Conjugates
    • 5.2.4 Hydrogel Nanoparticles
    • 5.2.5 Dendrimers
    • 5.2.6 Inorganic Nanoparticles
  • 5.3 Nano Tubes
  • 5.4 Nano Devices
  • 5.5 Nano Shells
  • 5.6 Other Product Types

6 Global Nanomedicine Market, By Modality

  • 6.1 Introduction
  • 6.2 Treatment
  • 6.3 Diagnostics

7 Global Nanomedicine Market, By Indication

  • 7.1 Introduction
  • 7.2 Clinical Oncology
  • 7.3 Infectious Diseases
  • 7.4 Clinical Cardiology
  • 7.5 Urology
  • 7.6 Ophthalmology
  • 7.7 Immunology
  • 7.8 Cardiovascular Diseases
  • 7.9 Orthopedic Diseases
  • 7.10 Neurological Diseases
  • 7.11 Anti-Inflammatory Diseases
  • 7.12 Anti-Infective Diseases
  • 7.13 Other Indications

8 Global Nanomedicine Market, By Application

  • 8.1 Introduction
  • 8.2 Drug Delivery
  • 8.3 Diagnostic Imaging
  • 8.4 In vitro Diagnostics
  • 8.5 Implants
  • 8.6 Regenerative Medicine
  • 8.7 Vaccines
  • 8.8 In-Vitro Imaging
  • 8.9 Therapeutics
  • 8.10 In-vivo Imaging
  • 8.11 Other Applications

9 Global Nanomedicine Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 NanoCarrier Co. Ltd
  • 11.2 Sanofi SA
  • 11.3 Leadient BioSciences Inc.
  • 11.4 Celgene Corporation
  • 11.5 Abbott Laboratories
  • 11.6 CombiMatrix Corporation
  • 11.7 Johnson & Johnson Services Inc
  • 11.8 Mallinckrodt Pharmaceuticals
  • 11.9 Nanobiotix
  • 11.10 Merck & Co., Inc.
  • 11.11 Nanospectra Biosciences, Inc.
  • 11.12 Gilead Sciences, Inc.
  • 11.13 Arrowhead Pharmaceuticals, Inc.
  • 11.14 Novavax, Inc.
  • 11.15 Pfizer, Inc.
  • 11.16 Teva Pharmaceutical Industries Ltd.
  • 11.17 GE Healthcare
  • 11.18 Taiwan Liposome Company Ltd
  • 11.19 Genzyme Corporation

List of Tables

  • Table 1 Global Nanomedicine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nanomedicine Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Nanomedicine Market Outlook, By Nanoparticles (2021-2030) ($MN)
  • Table 4 Global Nanomedicine Market Outlook, By Metal & Metal Oxide Nanoparticles (2021-2030) ($MN)
  • Table 5 Global Nanomedicine Market Outlook, By Liposomes (2021-2030) ($MN)
  • Table 6 Global Nanomedicine Market Outlook, By Polymers & Polymer Drug Conjugates (2021-2030) ($MN)
  • Table 7 Global Nanomedicine Market Outlook, By Hydrogel Nanoparticles (2021-2030) ($MN)
  • Table 8 Global Nanomedicine Market Outlook, By Dendrimers (2021-2030) ($MN)
  • Table 9 Global Nanomedicine Market Outlook, By Inorganic Nanoparticles (2021-2030) ($MN)
  • Table 10 Global Nanomedicine Market Outlook, By Nano Tubes (2021-2030) ($MN)
  • Table 11 Global Nanomedicine Market Outlook, By Nano Devices (2021-2030) ($MN)
  • Table 12 Global Nanomedicine Market Outlook, By Nano Shells (2021-2030) ($MN)
  • Table 13 Global Nanomedicine Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 14 Global Nanomedicine Market Outlook, By Modality (2021-2030) ($MN)
  • Table 15 Global Nanomedicine Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 16 Global Nanomedicine Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 17 Global Nanomedicine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 18 Global Nanomedicine Market Outlook, By Clinical Oncology (2021-2030) ($MN)
  • Table 19 Global Nanomedicine Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 20 Global Nanomedicine Market Outlook, By Clinical Cardiology (2021-2030) ($MN)
  • Table 21 Global Nanomedicine Market Outlook, By Urology (2021-2030) ($MN)
  • Table 22 Global Nanomedicine Market Outlook, By Ophthalmology (2021-2030) ($MN)
  • Table 23 Global Nanomedicine Market Outlook, By Immunology (2021-2030) ($MN)
  • Table 24 Global Nanomedicine Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 25 Global Nanomedicine Market Outlook, By Orthopedic Diseases (2021-2030) ($MN)
  • Table 26 Global Nanomedicine Market Outlook, By Neurological Diseases (2021-2030) ($MN)
  • Table 27 Global Nanomedicine Market Outlook, By Anti-Inflammatory Diseases (2021-2030) ($MN)
  • Table 28 Global Nanomedicine Market Outlook, By Anti-Infective Diseases (2021-2030) ($MN)
  • Table 29 Global Nanomedicine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 30 Global Nanomedicine Market Outlook, By Application (2021-2030) ($MN)
  • Table 31 Global Nanomedicine Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 32 Global Nanomedicine Market Outlook, By Diagnostic Imaging (2021-2030) ($MN)
  • Table 33 Global Nanomedicine Market Outlook, By In vitro Diagnostics (2021-2030) ($MN)
  • Table 34 Global Nanomedicine Market Outlook, By Implants (2021-2030) ($MN)
  • Table 35 Global Nanomedicine Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 36 Global Nanomedicine Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 37 Global Nanomedicine Market Outlook, By In-Vitro Imaging (2021-2030) ($MN)
  • Table 38 Global Nanomedicine Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 39 Global Nanomedicine Market Outlook, By In-vivo Imaging (2021-2030) ($MN)
  • Table 40 Global Nanomedicine Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.